Compare AKBA & EAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AKBA | EAF |
|---|---|---|
| Founded | 2007 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.0M | 429.4M |
| IPO Year | 2014 | 2018 |
| Metric | AKBA | EAF |
|---|---|---|
| Price | $1.40 | $9.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | $5.25 | ★ $11.75 |
| AVG Volume (30 Days) | ★ 2.2M | 248.7K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $504,134,000.00 |
| Revenue This Year | N/A | $4.25 |
| Revenue Next Year | N/A | $12.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.14 | $0.57 |
| 52 Week High | $4.08 | $20.32 |
| Indicator | AKBA | EAF |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 71.85 |
| Support Level | $1.30 | $7.65 |
| Resistance Level | $1.56 | $10.75 |
| Average True Range (ATR) | 0.08 | 0.62 |
| MACD | -0.00 | 0.30 |
| Stochastic Oscillator | 33.90 | 96.32 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.